Psilocybin
DOSED 2 screening sells out at Vancouver’s Rio Theatre
Film screening was followed by audience Q&A session hosted by director
The post DOSED 2 screening sells out at Vancouver’s Rio Theatre appeared…
A new film lit up the screen at Rio Theatre on Monday night, helping to propel the psychedelic renaissance through the power of documentary filmmaking.
DOSED 2: The Trip of a Lifetime has now made another appearance in Vancouver following a previous screening at Vogue Theatre in August.
Doors opened at 5 p.m. prior to the 6:30 screening and guests had the opportunity to mingle with various members of the psychedelic community, including the team from Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) and representatives from the Vancouver Psychedelic Society and Medicinal Mushroom Dispensary.
The screening event had a full house on Monday night and many had to seek seating on the upper balcony once the chairs on the main floor had been taken.
Read more: DOSED 2 set to premiere at Vogue Theatre in Vancouver
Read more: Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient
The documentary film tells the story of Laurie, a terminally ill cancer patient and mother of four in her early 50s who has been granted legal access to psilocybin mushrooms through the Special Access Program (SAP) from Health Canada to help alleviate her end-of-life anxiety.
Following an immensely powerful initial experience with magic mushrooms, Laurie embarks on an incredible journey of self-discovery and healing, eventually harnessing the power of cannabis oil as well.
Renowned psychedelic community figures featured in the film included Dr. Gabor Mate, a prominent addiction specialist and author; Benjamin Lightburn, CEO of Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS); Dana Larsen, owner of the Medicinal Mushroom Dispensary; and Paul Stamets, a world-renowned mycologist and psychedelic researcher.
Through the use of medicines once considered to be unconventional, Laurie is currently fighting a winning battle with cancer and was in attendance for the Q&A following the film.
“This has been a really hard journey, but there’s a richness to life that wasn’t there before,” said Laurie.
When asked by someone in the audience if she planned on doing psilocybin again, Laurie responded by saying, “Actually, I’m doing it again in a few weeks.”
Laurie’s husband Glen was asked if he had taken a mushroom trip and he said, “Yes I have, it was the most profound thing I’ve ever experienced and one of the hardest things I’ve ever done.”
Dr. Neil Barclay from Numinus contributed by adding that “It’s incredible how safe psilocybin is, as a medical doctor when you look at how safe it is it’s quite remarkable. We haven’t figured out what the lethal dose is yet, it’s estimated that you would have to eat your body weight in fresh mushrooms to die and I challenge everyone out there to consider eating 70 kilograms of any sort of mushroom, psychedelic or not.”
The audience thought that comment was quite amusing and laughter echoed throughout the theatre.
“Most adverse effects that people experience with psilocybin are very manageable things,” said Barclay.
Nausea, some people have vomiting and other psychological effects, and a lot of times as the medicine starts people can feel a sense of apprehension and anxiety. There are also experiences many confront during the psychedelic journey which can be very challenging, scary or terrifying, but a lot of people will find that those frightening experiences are in fact the things that bring them the most benefit,” he added.
“You get the journey that you need not the journey that you want,” Barclay concluded.
The post DOSED 2 screening sells out at Vancouver’s Rio Theatre appeared first on Mugglehead Magazine.
psilocybin medicinal mushroom psychedelic numinus wellness numinus field trip filament health mushroom filament health canada-
Law & Regulation1 week ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics6 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics5 days ago
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation7 days ago
AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Psychedelics6 days ago
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
-
Psychedelics6 days ago
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
-
Psychedelics6 days ago
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
-
Law & Regulation5 days ago
FDA nod fuels Filament’s psychedelics push, but cash running short